Rosuvastatin as a Supplemental Treatment for the Clinical Symptoms of Nephropathia Epidemica: A Pilot Clinical Study

• Published in: Viruses Vol. 16; no. 2; p. 306
• Main Authors: Shakirova, Venera, Markelova, Maria, Davidyuk, Yuriy, Stott-Marshall, Robert J, Foster, Toshana L, Khaiboullina, Svetlana, Rizvanov, Albert, Martynova, Ekaterina
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01-02-2024; MDPI
• Subjects: Antibodies; Chemokines; Cholesterol; Cholesterol, LDL; Cytokine storm; Cytokines; Dosage and administration; Drug therapy; Drug therapy, Combination; Ethics; Fever; Hantavirus; Hemorrhagic fever; Hemorrhagic fever with renal syndrome; Hemorrhagic Fever with Renal Syndrome - diagnosis; High density lipoprotein; Hospitalization; Humans; Infections; Infectious diseases; Inflammation; Kidney diseases; Kidneys; Lipids; Low density lipoprotein; Medical treatment; nephropathia epidemica; Osteopontin; Pathogenesis; Patients; Rosuvastatin; Rosuvastatin Calcium - therapeutic use; Serum levels; Signal transduction; Statins; Testing; Toxicity; Triglycerides; Tumor necrosis factor-TNF; Zoonoses; Russia; United States > US; rosuvastatin; statins; nephropathia epidemica
• ISSN: 1999-4915; 1999-4915
• DOI: 10.3390/v16020306

Nephropathis epidemica (NE), a mild form of hemorrhagic fever with renal syndrome (HFRS), is an acute zoonotic disease endemic in the Republic of Tatarstan. This study aimed to assess the impact of rosuvastatin on the clinical and laboratory results of NE. A total of 61 NE patients and 30 controls were included in this study; 22 NE patients and 7 controls received a daily dose of rosuvastatin (10 mg) for ten consecutive days. Serum samples were collected on days 1, 5, and 10 after admission to the hospital. These samples were analyzed to determine the levels of lipids, cytokines, and kidney toxicity markers. Our findings indicate that rosuvastatin reduced the duration of the second wave of fever and alleviated back pain and headache symptoms. Additionally, low-density lipoprotein cholesterol (LDL-C) serum levels were significantly decreased on days 5 and 10 upon rosuvastatin treatment. Furthermore, rosuvastatin decreased the levels of cytokines in the serum, particularly proinflammatory cytokines IL-1β and IL-8. NE patients had significantly altered levels of the kidney toxicity markers albumin and osteopontin. The data from our study provide evidence supporting the therapeutic potential of rosuvastatin in NE cases.